Live feed10:19:00·297dPRReleasevia QuantisnowBaxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
